Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses.
Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate monophosphate (cGMP) specifically to 5' GMP. PDE5 inhibitors were a breakthrough medication that addressed a previously unfulfilled medical need. They promoted vascular relaxation in the corpora cavernosa and penile erection during sexual stimulation. Sildenafil, vardenafil, and tadalafil were approved then introduced as effective treatments for male erectile dysfunction. This impact has stimulated academic, clinical, and industrial research.
Version: za2963e q8zae q8zb3 q8zc4 q8zd9 q8ze4 q8zfe q8zga